Sun Pharmaceutical Industries · NSE: SUNPHARMA · BSE: 524715
Q2 FY21 results · Jul–Sep 2020
Sun Pharmaceutical Industries reported revenue from operations of ₹8,553.13 crore (up 5.3% from Q2 FY20) and net profit of ₹1,942.76 crore (up 67.0% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 8,553.13 | 8,123.35 | +5.3% | 7,585.25 | +12.8% |
| Other income | 255.78 | 200.85 | +27.3% | 153.79 | +66.3% |
| Total income | 8,808.91 | 8,324.20 | +5.8% | 7,739.04 | +13.8% |
| Profit before share of associates & JVs and tax | 1,917.18 | 1,433.38 | +33.8% | (2,183.90) | Turned profit |
| Share of profit/(loss) of associates & JVs | (5.62) | (4.18) | 3.58 | ||
| Net profit for the period | 1,942.76 | 1,163.17 | +67.0% | (2,426.23) | Turned profit |
| Attributable to shareholders of the company | 1,812.79 | 1,064.09 | +70.4% | (1,655.60) | Turned profit |
| EPS, basic (₹) | 7.56 | 4.43 | not comparable | (6.90) | not comparable |
| Net margin (%) | 22.7 | 14.3 | -32.0 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 3,292.51 | 3,373.29 | −2.4% | 2,963.04 | +11.1% |
| Other income | 73.18 | 258.33 | −71.7% | 21.19 | +245.4% |
| Total income | 3,365.69 | 3,631.62 | −7.3% | 2,984.23 | +12.8% |
| Profit before tax | 701.88 | 839.63 | −16.4% | 531.52 | +32.1% |
| Net profit for the period | 724.81 | 823.16 | −11.9% | 531.95 | +36.3% |
| EPS, basic (₹) | 3.02 | 3.43 | not comparable | 2.22 | not comparable |
| Net margin (%) | 22.0 | 24.4 | 18.0 |
Consolidated
- Filed with BSE
- 04 Nov 2020, 14:36 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 04 Nov 2020, 14:36 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE